Amyotrophic Lateral Sclerosis (ALS)

ALS Research: MDA Hosts 'Think Tank'

 

An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in the field and senior MDA staff in Tucson, Ariz., on Saturday, Oct. 24, 2009.

Each specialist introduced his or her area of expertise and led an approximately 20-minute discussion, gathering input and answering questions from the other participants.

ALS Research: MDA Hosts 'Think Tank'

An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in the field and senior MDA staff in Tucson, Ariz., on Saturday, Oct. 24, 2009.

Each specialist introduced his or her area of expertise and led an approximately 20-minute discussion, gathering input and answering questions from the other participants.

ALS Research: APC & ALS

A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.

ALS Research: APC & ALS

A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.

MDA Hosts One-Day ALS 'Think Tank'

Neurologist Valerie Cwik, senior executive vice president-research and medical director at MDA, and neurologist Stan Appel

Drug Used to Treat Sepsis Shows Promise in Mice with ALS

A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.

ALS Research: Blocking SOD1

A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

ALS Research: Blocking SOD1

A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

ALS TDI Webcast

A Webcast is now available of the fourth annual research symposium held as part of the ALS TDI Leadership Summit 2009 on Oct. 5. The symposium was conducted at the MDA-supported ALS Therapy Development Institute in Cambridge, Mass.

ALS TDI Webcast

A Webcast is now available of the fourth annual research symposium held as part of the ALS TDI Leadership Summit 2009 on Oct. 5. The symposium was conducted at the MDA-supported ALS Therapy Development Institute in Cambridge, Mass.

Pages